Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review

References

• World Health Organization. Global advisory committee on vaccine safety, 3-4 Dec 2003. Weekly Epidemiological Rec. 2004;79(3):16–20. https://apps.who.int/iris/handle/10665/232366
   PubMedGoogle Scholar
• Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunisation: vaccine adverse event reporting system (VAERS) – United States, 1991–2001. MMWR Surveill Summ. 2003;52:1–24.
   PubMedGoogle Scholar
• Schuchat A. Human vaccines and their importance to public health. Procedia Vaccinol. 2011;5:120–126.
   Google Scholar
• Tavako S, Alavijeh MS, Seifalian AM. COVID-19 vaccines on clinical trials and their mode of action for immunity against the virus. Curr Pharm Des. 2021;27(13):1553–1563.
   PubMed Web of Science ®Google Scholar
• Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24:2012–2019.
   PubMed Web of Science ®Google Scholar
• Meo SA, Al-Khlaiwi T, Usmani AM, et al. Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19. J King Saud Univ Sci. 2020;32:2495–2499.
   PubMed Web of Science ®Google Scholar
• Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. Nat Human Behav. 2021;27:1–7.
   Google Scholar
• Tourni M, Ricciardi W. The economic value of vaccination: why prevention is wealth. J Mark Access Health Policy. 2015;3:29414.
   Google Scholar
• World Health Organization. 2021. Guidance document: status of COVID-19 vaccines within WHO EUL/PQ evaluation process. [cited 2022 Jun 05]: Available at: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_15July2021.pdf
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187–2201.
   PubMed Web of Science ®Google Scholar
• Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305–306.
   PubMed Web of Science ®Google Scholar
• Van Riel D, Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19:810–812.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383:1920–1931.
   PubMed Web of Science ®Google Scholar
• Xia X. Detailed dissection and critical evaluation of the pfizer/biontech and moderna mRNA vaccines. Vaccines (Basel). 2021;9(7):734.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82.
   PubMed Web of Science ®Google Scholar
• Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372.
   PubMed Web of Science ®Google Scholar
• Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE. 2012;7(7):e40385.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478.
   PubMed Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(2):279–288.
   PubMed Web of Science ®Google Scholar
• Harder T, Koch J, Vygen-Bonnet S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021;26(28):2100563.
   PubMedGoogle Scholar
• Harder T, Külper-Schiek W, Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill. 2021;26(41):2100920.
   PubMedGoogle Scholar
• Higdon MM, Wahl B, Jones CB, et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. Open Forum Infect Dis. 2021;9(6):ofac138.
   Web of Science ®Google Scholar
• Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021;29:1075–1090.
   PubMed Web of Science ®Google Scholar
• Meggiolaro A, Schepisi MS, Nikolaidis G, et al. Effectiveness of vaccination against symptomatic and asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Vaccines (Basel). 2022;10(2):157.
   PubMedGoogle Scholar
• Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200.
   PubMed Web of Science ®Google Scholar
• McCartney PR. Sex-Based vaccine response in the context of COVID-19. J Obstet Gynecol Neonatal Nurs. 2020;49:405–408.
   PubMed Web of Science ®Google Scholar
• Vijayasingham L, Bischof E, Wolfe J. Sex-Disaggregated data in COVID-19 vaccine trials. Lancet. 2021;397:966–967.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (ed). 2012. Appendix F Quality appraisal checklist – quantitative intervention studies. London: Methods for the Development of NICE Public Health Guidance. https://www.nice.org.uk/process/pmg4/chapter/about-this-document.
   Google Scholar
• Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11: 2601-2601.
   Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. Sars-Cov-2 MRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571.
   PubMed Web of Science ®Google Scholar
• Sun Z, Ren K, Zhang X, et al. Mass spectrometry analysis of newly emerging coronavirus HCoV-19 spike S protein and human ACE2 reveals camouflaging glycans and unique post-translational modifications. Engineering (Beijing). 2021;7(10):1441–1451.
   PubMedGoogle Scholar
• Kontopoulou K, Ainatzoglou A, Ifantidou A, et al. Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers. J Med Microbiol. 2021;70(8):001387.
   PubMedGoogle Scholar
• Voysey M, Clemens S, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21:1107–1119.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) covid-19 vaccine. N Engl J Med. 2021;385(25):2348–2360.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593.
   PubMed Web of Science ®Google Scholar
• Shang W, Yang Y, Rao Y, et al. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020;5:18.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nature Rev Drug Discov. 2018;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Doerfler W. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 vaccines: possible integration into the human genome - are adenoviral genes expressed in vector-based vaccines? Virus Res. 2021;302:198466.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Viral vectors for COVID-19 vaccine development. Viruses. 2021;13(2):317.
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–221.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–1773.
   PubMed Web of Science ®Google Scholar
• Coggins SA, Laing ED, Olsen CH, et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. Open Forum Infect Dis. 2021;9(1):ofab575.
   PubMed Web of Science ®Google Scholar
• Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–250.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438.
   PubMed Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969–1973.
   PubMed Web of Science ®Google Scholar
• Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA. 2020;324(5):439–440.
   PubMed Web of Science ®Google Scholar
• Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020;395:1751–1752.
   PubMed Web of Science ®Google Scholar
• Collins FS, Stoffels P. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323:2455–2457.
   PubMed Web of Science ®Google Scholar